CHAPTER 46
Acute Gastrointestinal Hemorrhage
OUTLINE
Management of Patients With Acute Gastrointestinal Hemorrhage
Acute Upper Gastrointestinal Hemorrhage
Acute Lower Gastrointestinal Hemorrhage
Acute Gastrointestinal Hemorrhage from an Obscure Source
Acute gastrointestinal (GI) hemorrhage is a common clinical
problem with diverse manifestations. Such bleeding may range
from trivial to massive and can originate from virtually any region
of the GI tract, including the pancreas, liver, and biliary tree. The
site of bleeding is typically classified by the location relative to
the ligament of Treitz. Upper GI hemorrhage from proximal to
the ligament of Treitz is the most common site of acute GI bleed-
ing. Peptic ulcer disease and variceal hemorrhage are the most
common causes. Most of the lower GI bleeding is from the colon,
with diverticula and angiodysplasias accounting for the majority
of cases. In other cases, the small intestine is responsible. Obscure
bleeding is defined as hemorrhage that persists or recurs after
negative evaluation with endoscopy. Occult bleeding is not appar-
ent to the patient until symptoms related to the anemia are
manifested.
During the past 20 years, multiple factors have influenced the
incidence of this disease. Increased use of certain medications
(e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] and selec-
tive serotonin reuptake inhibitors [SSRIs]) has increased preva-
lence of GI bleeding, whereas the use of proton pump inhibitors
(PPIs) and agents that eradicate Helicobacter pylori has decreased
the incidence of bleeding. The overall result is that the rate of
hospitalization for GI bleeding has declined modestly by 4%
between 1998 and 2006.1 A national estimate of patient dis-
charges with a primary diagnosis of GI bleeding in 2006 was 187
discharges per 100,000 capita. The incidence of GI bleeding
increased with age, occurring in approximately 1% of those 85
years or older (1187 hospital discharges with primary diagnosis
of GI bleeding per 100,000 capita).1 Although the total economic
burden of GI hemorrhage has not been formally assessed, cost of
a hospital admission for upper GI bleeding has been estimated to
be about $20,000 per admission with a direct in-hospital eco-
nomic burden of $7.6 billion in 2009.2 Importantly, patients who
experience an upper GI bleed also have significantly higher health
resource utilization and costs during the subsequent 12 months
than patients without bleeding.3
Management of these patients is frequently multidisciplinary,
involving emergency medicine, gastroenterology, intensive care,
surgery, and interventional radiology. The importance of early
surgical consultation in the care of these patients cannot be
Ali Tavakkoli, Stanley W. Ashley
overemphasized. In addition to aiding in the resuscitation of the
unstable patient, the surgical endoscopist in some settings estab-
lishes the diagnosis and initiates therapy. Even when the gastro-
enterologist assumes this role, early surgical consultation is
recommended, especially in high-risk patients. Approximately 5%
of patients, usually those who are often older and sicker, require
surgical intervention.4 Early consultation allows the establishment
of treatment goals and limits for the initial nonoperative therapy
and more time for preoperative preparation and evaluation as well
as patient and family education should urgent surgical interven-
tion become necessary.
Most patients with an acute GI hemorrhage stop bleeding
spontaneously. This allows time for a more elective evaluation.
However, in almost 15% of cases, major bleeding persists, requir-
ing emergent resuscitation, evaluation, and treatment. Improve-
ments in the management of such patients, primarily by means
of endoscopy and directed therapy, have significantly reduced the
length of hospitalization and overall mortality in the United States
to 3%, with mortality rates of 10% reported by other groups,
especially in the older patients.4
Determination of the site of bleeding is important for directing
diagnostic interventions with minimal delay. However, attempts
to localize the source should never precede appropriate resuscita-
tive measures.
MANAGEMENT OF PATIENTS WITH ACUTE
GASTROINTESTINAL HEMORRHAGE
In patients with GI bleeding, several fundamental principles of
initial evaluation and management must be followed. A well-
defined and logical approach to the patient with GI hemorrhage
is outlined in Figure 46-1. On presentation, a rapid initial assess-
ment permits a determination of the urgency of the situation.
Resuscitation is initiated with stabilization of the patient’s hemo-
dynamic status and the establishment of a means for monitoring
ongoing blood loss. A careful history and physical examination
should provide clues to the cause and source of the bleeding and
identify any complicating conditions or medications. Specific
investigation should then proceed to refine the diagnosis.
1139
1140 SECTION X Abdomen
Initial assessment and resuscitation
Assess airway, breathing, and circulation (ABCs)
Assess magnitude of bleeding
Initiate appropriate monitoring
Laboratory evaluation
History and exam
Identify risk factors
Previous surgery
Medications
Localize bleeding
Endoscopy
Possible nasogastric tube aspirate
Other studies as needed
Initiate therapy
Pharmacologic
Endoscopic
Angiographic
Surgical
FIGURE 46-1 General approach to patients with acute GI hemorrhage.
Therapeutic measures are then initiated, and bleeding is controlled
and recurrent hemorrhage prevented.
Initial Assessment
The presentation of GI bleeding is variable, ranging from
hemoccult-positive stool on rectal examination to exsanguinating
hemorrhage; thus, a structured approach to the assessment is
important. Adequacy of the patient’s airway and breathing take
first priority.5 Once these are ensured, the patient’s hemodynamic
status becomes the dominant concern and forms the basis for
further management. Initial evaluation should focus on rapid
assessment of the magnitude of both the preexisting deficits and
ongoing hemorrhage. Continuous reassessment of the patient’s
circulatory status determines the aggressiveness of subsequent
evaluation and intervention. The history of the bleeding, both its
magnitude and frequency, should also provide some guidance.
The severity of the hemorrhage can be generally determined
on the basis of simple clinical parameters. Obtundation, agitation,
and hypotension (systolic blood pressure <90 mm Hg in the
supine position) associated with cool, clammy extremities are
consistent with hemorrhagic shock and suggest a loss of more than
40% of the patient’s blood volume. A resting heart rate above 100
beats/min with a decreased pulse pressure implies a 20% to 40%
volume loss. In patients without shock, postural changes should
be elicited by allowing the patient to sit up with the legs dangling
for 5 minutes. A fall in blood pressure of more than 10 mm Hg
or an elevation of the pulse of more than 20 beats/min again
reflects at least a 20% blood loss. Patients with lesser degrees of
bleeding may have no detectable alterations.
The hematocrit is not a useful parameter for assessing the
degree of hemorrhage in the acute setting because the proportion
of red blood cells (RBCs) and plasma initially lost is constant. The
hematocrit does not fall until plasma is redistributed into the
intravascular space and resuscitation with crystalloid solution is
begun. Likewise, the absence of tachycardia may be misleading;
some patients with severe blood loss may actually have bradycar-
dia secondary to vagal slowing of the heart. Hemodynamic signs
are less reliable in the elderly and patients taking beta blockers.
Resuscitation
The more severe the bleeding, the more aggressive the resuscita-
tion. In fact, the single leading cause of morbidity and mortality
in these patients is multiorgan failure related to inadequate initial
or subsequent resuscitation. Intubation and ventilation should be
initiated early if there is any question of airway compromise. In
patients with evidence of hemodynamic instability or those in
whom ongoing bleeding is suspected, two large-bore intravenous
lines should be placed, preferably in the antecubital fossae. Unsta-
ble patients should receive a 2-liter bolus of crystalloid solution,
usually lactated Ringer solution , which most closely approximates
the electrolyte composition of whole blood. The response to the
fluid resuscitation should be noted. Blood should immediately be
sent for type and crossmatch, hematocrit, platelet count, coagula-
tion profile, routine chemistries, and liver function tests. A Foley
catheter should also be inserted for assessment of end-organ perfu-
sion. The oxygen-carrying capacity of the blood can be maximized
by administering supplemental oxygen. Frequently, these patients
benefit from early admission to and management in the intensive
care unit (ICU).
The decision to transfuse blood depends on the response to the
fluid challenge, the age of the patient, whether concomitant car-
diopulmonary disease is present, and whether the bleeding con-
tinues. The initial effects of crystalloid infusion and the patient’s
ongoing hemodynamic parameters should be the primary criteria.
Once again, this process requires an element of clinical judgment.
For example, a young, healthy patient with an estimated blood
loss of 20% who responds to the fluid challenge with a normaliza-
tion of hemodynamics may not need any blood products, whereas
an elderly patient with a significant cardiac history and the same
blood loss probably requires a transfusion. In general, the hema-
tocrit should be maintained above 30% in the elderly and above
20% in young, otherwise healthy patients. Likewise, the propen-
sity of the suspected lesion to continue bleeding or to rebleed
must play a role in this decision. For example, esophageal varices
are very likely to continue to bleed and transfusion might be
considered earlier than if a Mallory-Weiss tear, which has a low
rebleeding rate, is considered the culprit. In general, packed RBCs
are the preferred form of transfusion, although whole blood,
preferably warmed, may be employed in circumstances of massive
blood loss. Defects in coagulation and platelets should be replaced
as they are detected, and patients who require high-volume trans-
fusion should empirically receive both fresh-frozen plasma and
platelets and calcium.
History and Physical Examination
Once the severity of the bleeding is assessed and resuscitation
initiated, attention is directed to the history and physical examina-
tion. The history helps to make a preliminary assessment of the
site and cause of bleeding and of significant medical conditions
that may determine or alter the course of management.
Obviously, the characteristics of the bleeding provide impor-
tant clues. The time at onset, volume, and frequency are impor-
tant in estimating blood loss. Hematemesis, melena, and
hematochezia are the most common manifestations of acute hem-
orrhage. Hematemesis is the vomiting of blood and is usually
caused by bleeding from the upper GI tract, although rarely
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1141

bleeding from the nose or pharynx can be responsible. It may be
bright red or older and therefore take on the appearance of coffee
grounds. Melena, the passage of black, tarry, and foul-smelling
stool, generally suggests bleeding from the upper GI tract.
Although the melanotic appearance typically results from gastric
acid degradation, which converts hemoglobin to hematin, and
from the actions of digestive enzymes and luminal bacteria in the
small intestine, blood loss from the distal small bowel or right
colon may have this appearance, particularly if transit is slow
enough. Melena should not be confused with the greenish char-
acter of the stool in patients taking iron supplements. One way
to distinguish these two is by performing a guaiac test, the result
of which is negative in those receiving iron supplementation.
Hematochezia refers to bright red blood from the rectum that
may or may not be mixed with stool. Although this typically
reflects a distal colonic source, if the magnitude is significant, even
upper GI bleeds may produce hematochezia.
The medical history may provide a variety of clues to the
diagnosis. Antecedent vomiting may suggest a Mallory-Weiss tear,
whereas weight loss raises the specter of malignant disease. Even
demographic data may prove useful; the elderly bleed from lesions
such as angiodysplasias, diverticula, ischemic colitis, and cancer,
whereas younger patients bleed from peptic ulcers, varices, and
Meckel’s diverticula. A past history of GI disease, bleeding, or
operation should immediately begin to focus the differential diag-
nosis. Antecedent epigastric distress may point to a peptic ulcer,
whereas previous aortic surgery suggests the possibility of an aor-
toenteric fistula. A history of liver disease prompts a consideration
of variceal bleeding. Medication use may also be revealing. A
history of ingestion of salicylates, NSAIDs, and SSRIs is common,
particularly in the elderly.6 These medications are associated with
GI mucosal erosions that are typically seen in the upper GI tract
but that occasionally can be seen in the small bowel and colon.
GI bleeding in the setting of anticoagulation therapy, either war-
farin or low-molecular-weight heparin, is still most commonly the
result of GI disease and should not be ascribed to the anticoagula-
tion alone.7
Physical examination may also be revealing. The oropharynx
and nose can occasionally simulate symptoms of a more distal
source and should always be examined. Abdominal examination
is only occasionally helpful, but it is important to exclude masses,
splenomegaly, and adenopathy. Epigastric tenderness is suggestive
but not diagnostic of gastritis or peptic ulceration. The stigmata
of liver disease, including jaundice, ascites, palmar erythema, and
caput medusae, may suggest bleeding related to varices, although
these patients commonly bleed from other sources as well. On
occasion, the physical examination may reveal clues to more
obscure diagnoses, such as the telangiectasias of Osler-Weber-
Rendu syndrome or the pigmented lesions of the oral mucosa in
Peutz-Jeghers syndrome. A rectal examination and anoscopy
should be performed to exclude a low-lying rectal cancer or bleed-
ing from hemorrhoids.
Localization
Subsequent management of the patient with acute GI hemorrhage
depends on localization of the site of the bleeding. An algorithm
for the diagnosis of acute GI hemorrhage is shown in Figure 46-2.
Although melena is usually from the upper GI tract, it can be
the result of bleeding from the small bowel or colon. Likewise,
hematochezia is sometimes the consequence of brisk upper GI

Acute gastrointestinal hemorrhage

History and physical strongly

suggestive of site of bleeding
Can consider placing an NG
tube if source unclear

Upper GI bleed Lower GI bleed

EGD
Usually within Slow Massive
24 hrs hemorrhage hemorrhage

Diagnostic Non-Diagnostic
Colonoscopy Angiography

Slow Massive
hemorrhage hemorrhage
Diagnostic Non-Diagnostic
RBC scan Angiography
operation
RBC scan
Meckel’s scan
Capsule endoscopy
CT angiography

FIGURE 46-2 Algorithm for the diagnosis of acute GI hemorrhage.

1142 SECTION X Abdomen

bleeding. One approach to distinguishing these possibilities has BOX 46-1 Commonly Used Risk
been to insert a nasogastric (NG) tube and to perform a gastric
Stratification Systems for Upper
lavage with examination of the aspirate. Increasing data, however,
have shown that an NG tube is unreliable in localizing the bleed- Gastrointestinal Bleeds
ing site, and virtually all patients with significant bleeding should Blatchford Score
undergo upper endoscopy for direct visualization. Blood urea nitrogen
Upper endoscopy under these circumstances is highly accurate Hemoglobin
both in identifying an upper GI lesion and, if evaluation is nega- Systolic blood pressure
tive, in directing attention to a lower GI source. Early endoscopy Pulse
with directed therapy has been shown to reduce resource utiliza- Presence of melena, syncope, hepatic or cardiac dysfunction
tion and transfusion requirements and to shorten hospital stay.
The exact definition and timeline of an “early” endoscopy have Rockall Score
been well studied and refined. There is little argument that in an Age (<60 years, 60-79 years, >80 years)
unstable patient, an urgent endoscopy is often required; however, Comorbid disease (cardiac, hepatic, renal, or disseminated cancer)
in those patients with overt signs of bleeding but who are other- Magnitude of the hemorrhage (systolic blood pressure <100 mm Hg, heart
wise stable, endoscopy within 6 or 12 hours has not been shown rate >100 beats/min) on presentation
to be of any additional benefit compared with endoscopy per- Transfusion requirement
formed within 24 hours.8,9 Endoscopic findings (Mallory-Weiss tears, nonmalignant lesions, or malignant
Clinicians should be aware that esophagogastroduodenoscopy lesions)
(EGD) in the urgent or emergent setting is associated with Stigmata of recent bleed
reduced accuracy, often because of poor visualization, and a sig-
nificant increase in the incidence of complications, including
aspiration, respiratory depression, and GI perforation, compared
with elective procedures. Airway protection is critical and may TABLE 46-1 Common Causes of Upper
require endotracheal intubation if it has not been performed Gastrointestinal Hemorrhage
previously. Volume resuscitation should not be interrupted by the
examination. PORTAL
As shown in Figure 46-2, subsequent evaluation depends on NONVARICEAL HYPERTENSIVE
the results of the upper endoscopy and the magnitude of the BLEEDING 80% BLEEDING 20%
bleeding. Angiography or even surgery may prove necessary for Gastric and duodenal 30%-40% Gastroesophageal >90%
massive hemorrhage, precluding endoscopy, from either the upper ulcers varices
or lower GI tract. For slow or intermittent bleeding from the Gastritis or duodenitis 20% Hypertensive portal <5%
lower GI tract, colonoscopy is now the initial diagnostic maneuver gastropathy
of choice. When endoscopy is nondiagnostic, the tagged RBC Esophagitis 5%-10% Isolated gastric varices Rare
scan is usually employed. For obscure bleeding, usually from the Mallory-Weiss tears 5%-10%
small bowel, capsule endoscopy is becoming the appropriate Arteriovenous 5%
study. These diagnostic procedures are discussed subsequently in malformations
greater detail. Once the location of bleeding has been identified, Tumors 2%
appropriate therapy, as discussed in relevant sections later, can be Others 5%
initiated.

Risk Stratification
Not all patients with GI bleeding require hospital admission or
emergent evaluation. For example, the patient with a small
amount of rectal bleeding that has stopped can generally be evalu-
ated on an outpatient basis. In many patients, however, the deci-
sion is less straightforward, and considerable recent effort has been
devoted to the development of risk scoring tools to facilitate
patient triage. These scoring systems have been used to predict the
risk of rebleeding and mortality, to evaluate the need for ICU
admission, and to determine the need for urgent endoscopy. Some
scoring systems (e.g., APACHE II) are nonspecific to GI bleeding
but can provide general information about the patient’s condition
and risk of adverse outcomes.
There have also been attempts to develop disease-specific
scoring systems for upper GI bleeds. These scores help to identify
those at higher risk of major bleeding or death and who warrant
closer observation and more aggressive therapy. The commonly
used scoring systems are the Rockall score, which takes into
account endoscopic findings, and the Blatchford score, which
does not require endoscopic data and can be used during initial
assessment. Box 46-1 summarizes these scoring systems.
ACUTE UPPER GASTROINTESTINAL HEMORRHAGE
Upper GI bleeding refers to bleeding that arises from the GI tract
proximal to the ligament of Treitz and accounts for nearly 80%
of significant GI hemorrhage. The causes of upper GI bleeding
are best categorized as either nonvariceal sources or bleeding
related to portal hypertension (Table 46-1). The nonvariceal
causes account for approximately 80% of such bleeding, with
peptic ulcer disease being the most common.10 Although patients
with cirrhosis are at high risk for development of variceal bleeding,
nonvariceal sources can account for up to 50% of GI bleeds.
However, because of greater morbidity and mortality of variceal
bleeding, patients with cirrhosis should generally be assumed to
have variceal bleeding and appropriate therapy initiated until an
emergent endoscopy has demonstrated another cause for the
hemorrhage.
The foundation for the diagnosis and management of patients
with an upper GI bleed is an upper endoscopy. Multiple studies
have demonstrated that early EGD, within 24 hours, results in
reductions in blood transfusion requirements, a decrease in the
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1143

need for surgery, and a shorter length of hospital stay. Endoscopic

identification of the source of bleeding also permits an estimate EGD confirms peptic ulcer bleeding
of the risk of subsequent or persistent hemorrhage as well as
facilitates operative planning should that prove necessary. It is
somewhat surprising that studies have not shown any benefits in No Endoscopic findings
performing the endoscopies sooner (within 6 or 12 hours) than Forrest classification:
within 24 hours.8,9 Although the best tool for localization of the Ia, Ib, IIa, IIb
bleeding source is EGD, this intervention is associated with Yes
increased risk and poor visualization in the acute setting, which
may offset some of its benefits. In 1% to 2% of patients with Endoscopic therapy
upper GI hemorrhage, the source cannot be identified because of
the excessive blood impairing the visualization of the mucosal Yes
surface.11 Aggressive lavage of the stomach with room temperature Continuous bleeding
normal saline solution before the procedure can be helpful. Use
of promotility agents to enhance endoscopic visualization is not No
recommended.12 If upper GI bleed is confirmed but identification Monitor
of the actual source is still not possible, angiography may be
appropriate in the reasonably stable patient, although operative Assess for H. pylori
intervention should be seriously considered if the blood loss is No
Treat with PPI Rebleed?
extreme or the patient is hemodynamically unstable. Tagged RBC Repeat endoscopy for
scan is seldom necessary with a confirmed upper GI bleed, and gastric ulcer Yes Surgery
contrast studies are usually contraindicated because they will
Repeat endoscopy
interfere with subsequent maneuvers.

Specific Causes of Upper Gastrointestinal Hemorrhage Yes

Nonvariceal Bleeding Continuous bleeding?
Peptic ulcer disease. Peptic ulcer disease still represents the
No
most frequent cause of upper GI hemorrhage, accounting for
approximately 40% of all cases.13 Approximately 10% to 15% of Monitor
patients with peptic ulcer disease develop bleeding at some point
in the course of their disease. Bleeding is the most frequent indica-
No Yes
tion for operation and the principal cause for death in peptic Rebleeding
ulcer disease.14 Peptic ulcer disease is discussed in more detail in
Chapter 48; this discussion focuses only on bleeding from ulcer FIGURE 46-3 Algorithm for the diagnosis and management of nonvari-
disease. ceal upper GI bleeding.
The epidemiology of peptic ulcer has continued to change. The
incidence of uncomplicated peptic ulcer disease has declined dra-
matically. This recent change has been attributed to better medical TABLE 46-2 The Forrest Classification for
therapy, including the PPIs and regimens for eradication of H. Endoscopic Findings and Rebleeding Risks in
pylori. Along with this decline, there has also been a decline in Peptic Ulcer Disease
the number of hospitalizations for complicated peptic ulcer
CLASSIFICATION REBLEEDING RISK
disease and number of surgical interventions, including suture
repair of bleeding ulcers. When surgery for upper GI hemorrhage Grade Ia Active, pulsatile bleeding High
is undertaken, however, such operations are now typically per- Grade Ib Active, nonpulsatile bleeding High
formed in older patients with higher comorbidities.14 Grade IIa Nonbleeding visible vessel High
Bleeding develops as a consequence of acid-peptic erosion of Grade IIb Adherent clot Intermediate
the mucosal surface. Whereas chronic blood loss is common with Grade IIc Ulcer with black spot Low
any ulcer, significant bleeding typically results when there is Grade III Clean, nonbleeding ulcer bed Low
involvement of an artery of the submucosa or, with penetration
of the ulcer, of an even larger vessel. The most significant hemor-
rhage occurs when duodenal or gastric ulcers penetrate into After the index endoscopy, treatment strategies depend on the
branches of the gastroduodenal artery or left gastric arteries, appearance of the lesion at endoscopy. Endoscopic therapy is
respectively. instituted if bleeding is active or, when bleeding has already
Management. Figure 46-3 outlines an approach to manage- stopped, if there is a significant risk of rebleeding. The ability to
ment. As stated previously, patients with clinical evidence of a GI predict the risk of rebleeding permits prophylactic therapy, closer
bleed should receive an endoscopy within 24 hours, and while monitoring, and earlier detection of hemorrhage in high-risk
awaiting the EGD, they should be treated with a PPI. Although patients. The Forrest classification was developed in an attempt to
this approach has been shown to reduce the stigmata of a recent assess this risk on the basis of endoscopic findings and to stratify
hemorrhage at index endoscopy, it had no impact on clinical the patients into low-, intermediate-, and high-risk groups (Table
outcomes such as transfusion requirements, mortality, or need for 46-2). Endoscopic therapy is recommended in cases of active
surgery; despite this, it is believed to be a cost-effective interven- bleeding as well as for a visible vessel (Forrest I-IIa). In cases of
tion for those suspected to have an upper GI bleed.15 an adherent clot (Forrest IIb), the clot is removed and the
1144 SECTION X Abdomen
underlying lesion evaluated. Ulcers with a clean base or a black
spot, secondary to hematin deposition, are generally not treated
endoscopically. Approximately 25% of patients undergoing EGD
for upper GI bleed require an endoscopic intervention.14
Medical management. In cases of a confirmed peptic ulcer
bleed, PPIs have been shown to reduce the risk of rebleeding and
the need for surgical intervention. Therefore, patients with a sus-
pected or confirmed bleeding ulcer should be started on a PPI.12
Unlike perforated ulcers, which are commonly associated with H.
pylori infection, the association between H. pylori infection and
bleeding is less strong. Only 60% to 70% of patients with a bleed-
ing ulcer are H. pylori positive.16 This has generated some discus-
sion as to the importance of H. pylori treatment in patients with
a bleeding peptic ulcer. Several studies and a large meta-analysis,
however, have shown that H. pylori treatment and eradication, in
patients who test positive for the infection, result in decreased
rebleeding.17 Importantly, once the H. pylori infection has been
eradicated, there is no need for long-term acid suppression, and
there is no increased risk of further bleeding with this approach.18
International consensus guidelines also recommend that patients
treated for H. pylori should be tested to confirm eradication. Some
guidelines also recommend that those who tested negative during
the acute episode should be retested to confirm negative status.
This is due to reports of high false-negative results of H. pylori
testing during an acute bleed.12
In patients who are taking ulcerogenic medications such as
NSAIDs or SSRIs and present with a bleeding GI lesion, these
medications should be stopped. Patients should be started on a
nonulcerogenic alternative, if possible, after their acute bleeding
episode has resolved. In those taking NSAIDs, more specific
cyclooxygenase 2 inhibitors had been a promising alternative.
Concerns about the cardiotoxicity of these drugs have resulted in
their withdrawal from the market, reducing the clinical use of
these alternative medicines. Further affecting the popularity of
these medications have been population-based studies showing
that not all cyclooxygenase 2 inhibitors result in a decreased inci-
dence of upper GI complications.19 Therefore, an alternative
approach has been to identify ways to reduce the adverse GI side
effects of NSAIDs. To this end, studies have shown that H. pylori
eradication in patients who are about to start these medications
can reduce the incidence of adverse GI side effects, including
bleeding.20 These studies highlight the synergistic effect of H.
pylori eradication and NSAID use. Although this approach can
have a preventive role in regard to GI bleeding, NSAIDs cannot
be recommended for those who present with a bleed, even after
H. pylori eradication.21
Endoscopic management. Once the bleeding ulcer has been
identified, effective local therapy can be delivered endoscopically
to control the hemorrhage. The available endoscopic options
include epinephrine injection, heater probes, and coagulation as
well as the application of clips. Epinephrine injection (1 : 10,000)
to all four quadrants of the lesion is successful in controlling the
hemorrhage. It has been shown that large-volume injection
(>13 mL) is associated with better hemostasis, suggesting that the
endoscopic injection works, in part, by compressing the bleeding
vessel and inducing tamponade. Epinephrine injection alone is
associated with a high rebleeding rate; therefore, the standard
practice as recommended by international consensus guidelines is
to provide combination therapy. This usually means the addition
of thermal therapy to the injection. The sources of thermal energy
can be heater probes, monopolar or bipolar electrocoagulation,
and laser or argon plasma coagulation (APC). The most
FIGURE 46-4 Hemoclip applied to a bleeding duodenal lesion. (Cour-
tesy Linda S. Lee, MD, Brigham and Women’s Hospital.)
commonly used energy sources are electrocoagulation for bleeding
ulcers and APC for superficial lesions. A combination of injection
with thermal therapy achieves hemostasis in 90% of bleeding
peptic ulcer disease. Hemoclips (Fig. 46-4), which can be difficult
to apply, may be particularly effective in dealing with a spurting
vessel as they provide immediate control of hemorrhage.
Rebleeding of an ulcer is associated with a significant increase
in mortality, and careful observation of patients at high risk of
rebleeding using criteria previously described is important. In
those who rebleed, a second attempt at endoscopic control has
been validated and is recommended. A second attempt at endo-
scopic hemostasis is successful in 75% of patients.22 Although this
will fail in 25% of patients who will then require emergent
surgery, there does not appear to be any increase in morbidity or
mortality with this treatment approach. Therefore, most clinicians
would encourage a second attempt at endoscopic control before
subjecting the patient to surgery.
Surgical management. Despite significant advances in endo-
scopic therapy, approximately 10% of patients with bleeding
ulcers still require surgical intervention for effective hemostasis.14
However, identifying patients who are likely to fail to respond to
endoscopic therapy is difficult, and the timing of surgery is much
debated. To assist in this decision making, several clinical and
endoscopic parameters have been proposed that are thought to
identify patients at high risk for failed endoscopic therapy. The
clinical factors to consider are shock and a low hemoglobin level
at presentation. At the time of endoscopy, although the Forrest
classification is the most important indicator of rebleeding risk,
the location and size of the ulcer are also significant. Ulcers larger
than 2 cm, posterior duodenal ulcers, and gastric ulcers have
significantly higher risk of rebleeding.23,24 Patients with these char-
acteristics need closer monitoring and possibly earlier surgical
intervention. Clearly, clinical judgment and local expertise must
play a critical role in this decision.
Indications for surgery have traditionally been based on the
blood transfusion requirements. Increased blood transfusions have
been clearly associated with increased mortality. Although a less
definitive criterion than it was in the past, most surgeons still
consider an ongoing blood transfusion requirement in excess of 6
units an indication for surgical intervention, particularly in the
 CHAPTER 46 Acute Gastrointestinal Hemorrhage
BOX 46-2 Indications for Surgery in
Gastrointestinal Hemorrhage
Hemodynamic instability despite vigorous resuscitation (>6-unit transfusion)
Failure of endoscopic techniques to arrest hemorrhage
Recurrent hemorrhage after initial stabilization (with up to two attempts at
obtaining endoscopic hemostasis)
Shock associated with recurrent hemorrhage
Continued slow bleeding with a transfusion requirement exceeding
3 units/day
elderly, although an 8- to 10-unit loss may be more acceptable for
the younger population. Current indications for surgery for peptic
ulcer hemorrhage are summarized in Box 46-2. Secondary or rela-
tive indications include a rare blood type or difficult crossmatch,
refusal of transfusion, shock on presentation, advanced age, severe
comorbid disease, and a bleeding chronic gastric ulcer for which
malignancy is a concern.
The first priority at operation should be control of the hemor-
rhage. Once this is accomplished, a decision must be made about
the need for a definitive acid-reducing procedure. Each of these
steps varies, depending on whether the lesion is a duodenal or
gastric ulcer.
Duodenal ulcer. The first step in the operative management
for a duodenal ulcer is exposure of the bleeding site. Because most
of these lesions are in the duodenal bulb, longitudinal duode-
notomy or duodenopyloromyotomy is performed. Hemorrhage
can typically be controlled initially with pressure and then direct
suture ligation with nonabsorbable suture. When ulcers are posi-
tioned anteriorly, four-quadrant suture ligation usually suffices. A
posterior ulcer eroding into the pancreaticoduodenal or gastro-
duodenal artery may require suture ligature of the vessel proximal
and distal to the ulcer as well as placement of a U-stitch under-
neath the ulcer to control the pancreatic branches.
Once the bleeding has been addressed, a definitive acid-
reducing operation was traditionally considered. With the identi-
fication of the role of H. pylori infection in duodenal ulcer disease,
the utility of such a procedure has been questioned on the basis
of the argument that simple closure and subsequent treatment for
H. pylori infection should be sufficient to prevent recurrence. This
is reflected in current surgical practice, wherein rates of definitive
ulcer therapy (gastrectomy or vagotomy) in patients hospitalized
for peptic ulcer disease have declined significantly.
Historically, the choice between various operations has been
based on the hemodynamic condition of the patient and on
whether there is a long-standing history of refractory ulcer disease.
The various operations for peptic ulcer disease are discussed in
greater detail in Chapter 48. Because the pylorus has often been
opened in a longitudinal fashion to control the bleeding, closure
as a pyloroplasty combined with truncal vagotomy is the most
frequently used operation for bleeding duodenal ulcer. There is
some evidence to suggest that a parietal cell vagotomy may rep-
resent a better therapy for a bleeding duodenal ulcer in the stable
patient, although some of this benefit may be abrogated if the
pylorus has been divided. Today, inexperience of the surgeon with
this procedure may be the determining factor. In a patient who
has a known history of refractory duodenal ulcer disease or who
has failed to respond to more conservative surgery, antrectomy
with truncal vagotomy may be more appropriate. However, this
procedure is more complex and should be undertaken rarely in a
hemodynamically unstable patient.
1145
Gastric ulcer. For bleeding gastric ulcers, control of bleeding
is the immediate priority. Although this may initially require
gastrotomy and suture ligation, this alone is associated with a high
risk of rebleeding of almost 30%. In addition, because of a 10%
incidence of malignancy, gastric ulcer resection is generally indi-
cated. Simple excision alone is associated with rebleeding in as
many as 20% of patients, so distal gastrectomy is generally pre-
ferred, although ulcer excision combined with vagotomy and
pyloroplasty may be considered in the high-risk patient. Bleeding
ulcers of the proximal stomach near the gastroesophageal junction
are more difficult to manage. Proximal or near-total gastrectomies
are associated with a particularly high mortality in the setting of
acute hemorrhage. Options include distal gastrectomy combined
with resection of a tongue of proximal stomach to include the
ulcer or vagotomy and pyloroplasty combined with either wedge
resection or simple oversewing of the ulcer.
Mallory-Weiss tears. Mallory-Weiss tears are mucosal and
submucosal tears that occur near the gastroesophageal junction.
Classically, these lesions develop in alcoholic patients after a
period of intense retching and vomiting following binge drinking,
but they can occur in any patient who has a history of repeated
emesis. The mechanism, proposed by Mallory and Weiss in 1929,
is forceful contraction of the abdominal wall against an unrelaxed
cardia, resulting in mucosal laceration of the cardia as a result of
the increased intragastric pressure.
Such lesions account for 5% to 10% of cases of upper GI
bleeding. They are usually diagnosed on the basis of history.
Endoscopy is frequently employed to confirm the diagnosis. To
avoid missing the diagnosis, it is important to perform a retro-
flexion maneuver and to view the area just below the gastro-
esophageal junction. Most tears occur along the lesser curvature
and less commonly on the greater curve. Supportive therapy is
often all that is necessary because 90% of bleeding episodes are
self-limited, and the mucosa often heals within 72 hours.
In rare cases of severe ongoing bleeding, local endoscopic
therapy with injection or electrocoagulation may be effective.
Angiographic embolization, usually with absorbable material such
as a gelatin sponge, has been successfully employed in cases of
failed endoscopic therapy. If these maneuvers fail, high gastrot-
omy and suturing of the mucosal tear are indicated. It is impor-
tant to rule out the diagnosis of variceal bleeding in cases of failed
endoscopic therapy by a thorough examination of the gastro-
esophageal junction. Recurrent bleeding from a Mallory-Weiss
tear is uncommon.
Stress gastritis. Stress-related gastritis is characterized by the
appearance of multiple superficial erosions of the entire stomach,
most commonly in the body. It is thought to result from the
combination of acid and pepsin injury in the context of ischemia
from hypoperfusion states, although NSAIDs produce a similar
appearance. In the 1960s and 1970s, it was a commonly encoun-
tered lesion in critically ill patients, with significant morbidity and
mortality from bleeding. These lesions are different from the soli-
tary ulcerations, related to acid hypersecretion, that occur in
patients with severe head injury (Cushing ulcers). When stress
ulceration is associated with major burns, these lesions are referred
to as Curling ulcers. In contrast to NSAID-associated lesions,
significant hemorrhage from stress ulceration was a common phe-
nomenon. With improvements in the management of shock and
sepsis as well as widespread use of acid suppressive therapy, sig-
nificant bleeding from such lesions is rarely encountered.
In those who develop significant bleeding, acid suppressive
therapy is often successful in controlling the hemorrhage. In rare
1146 SECTION X Abdomen

cases when this fails, consideration should be given to administra- to 100% of cases. In cases that fail endoscopic therapy, angio-
tion of octreotide or vasopressin, endoscopic therapy, or even graphic coil embolization can be successful. If these approaches
angiographic embolization. Historically, such cases were more are unsuccessful, surgical intervention may be necessary; because
commonly seen and, at times, dealt with surgically. The surgical of difficulties in visualization and palpation of these lesions, prior
choices included vagotomy and pyloroplasty with oversewing of endoscopic tattooing can facilitate the procedure. A gastrostomy
the hemorrhage or near-total gastrectomy. These procedures is performed, and attempts are made at identifying the bleeding
carried mortality rates as high as 60%. Fortunately, they are source. The lesion can then be oversewn. In cases in which the
seldom necessary today. bleeding point is not identified, a partial gastrectomy may be
Esophagitis. The esophagus is infrequently the source for sig- necessary.
nificant hemorrhage. When it does occur, it is most commonly Gastric antral vascular ectasia. Also known as watermelon
the result of esophagitis. Esophageal inflammation secondary to stomach, gastric antral vascular ectasia (GAVE) is characterized
repeated exposure of the esophageal mucosa to the acidic gastric by a collection of dilated venules appearing as linear red streaks
secretions in gastroesophageal reflux disease leads to an inflamma- converging on the antrum in longitudinal fashion, giving it the
tory response that can result in chronic blood loss. Ulceration may appearance of a watermelon. Acute severe hemorrhage is rare in
accompany this, but the superficial mucosal ulcerations generally GAVE, and most patients present with persistent, iron deficiency
do not bleed acutely and are manifested as anemia or guaiac- anemia from continued occult blood loss. Endoscopic therapy is
positive stools. Various infectious agents may also cause esopha- indicated for persistent, transfusion-dependent bleeding and has
gitis, particularly in the immunocompromised host (Fig. 46-5). been reportedly successful in up to 90% of patients. The pre-
With infection, hemorrhage can occasionally be massive. Other ferred endoscopic therapy is APC (Fig. 46-8). Patients failing
causes of esophageal bleeding include medications, Crohn’s
disease, and radiation.
Treatment typically includes acid suppressive therapy. Endo-
scopic control of the hemorrhage, usually with electrocoagulation
or heater probe, is often successful. In patients with an infectious
cause, targeted therapy is appropriate. Surgery is seldom necessary.
Dieulafoy lesion. Dieulafoy lesions are vascular malformations
found primarily along the lesser curve of the stomach within 6 cm
of the gastroesophageal junction, although they can occur else-
where in the GI tract (Fig. 46-6). They represent rupture of
unusually large vessels (1 to 3 mm) found in the gastric submu-
cosa. Erosion of the gastric mucosa overlying these vessels leads
to hemorrhage. The mucosal defect is usually small (2 to 5 mm)
and may be difficult to identify.25 Given the large size of the
underlying artery, bleeding from a Dieulafoy lesion can be massive
(Fig. 46-7).
Initial attempts at endoscopic control are often successful.
Application of thermal or sclerosant therapy is effective in 80%

FIGURE 46-6 Dieulafoy lesion of the stomach. (Courtesy Linda S. Lee,

MD, Brigham and Women’s Hospital.)

FIGURE 46-5 Bleeding esophageal ulcer secondary to herpes esopha-

gitis. (Courtesy Scott A. Hande, MD, Brigham and Women’s FIGURE 46-7 Bleeding Dieulafoy lesion with a spurting vessel. (Cour-
Hospital.) tesy Marvin Ryou, MD, Brigham and Women’s Hospital.)
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1147

C
FIGURE 46-8 A, GAVE can be seen in the gastric antrum, giving the stomach a watermelon appearance.
B, APC therapy of GAVE. C, Post-therapy appearance of GAVE. (Courtesy David L. Carr-Locke, MD, Brigham
and Women’s Hospital.)

to respond to endoscopic therapy should be considered for
antrectomy.
Malignancy. Malignant neoplasms of the upper GI tract are
usually associated with chronic anemia or hemoccult-positive
stool rather than episodes of significant hemorrhage. On occasion,
malignant neoplasms will be manifested as ulcerative lesions that
bleed persistently. This is perhaps most characteristic of the GI
stromal tumor (GIST), although it may occur with a variety of
other lesions including leiomyomas and lymphomas. Although
endoscopic therapy is often successful in controlling these bleeds,
the rebleeding rate is high; therefore, when a malignant neoplasm
is diagnosed, surgical resection is indicated. The extent of resec-
tion is dependent on the specific lesion and whether the resection
is believed to be curative or palliative. Palliative resections for
control of bleeding usually entail wedge resections. Standard
cancer operations are indicated when possible, although this may
depend on the hemodynamic stability of the patient.
Aortoenteric fistula. Primary aortoduodenal fistulas are rare
lesions and likely to be fatal as they represent a rupture of the
aorta to the bowel. The more common entity seen clinically is a
graft-enteric erosion, which may develop in up to 1% of aortic
graft cases and can be manifested as a GI bleed (Fig. 46-9).
Although the interval between surgery and hemorrhage can be
days to years, the median interval is about 3 years. The sequence
is thought to involve development of a pseudoaneurysm at the
proximal anastomotic suture line in the setting of an infection,
with subsequent fistulization into the overlying duodenum.
This diagnosis should be considered in all bleeding patients
with a known abdominal aortic aneurysm or a previous prosthetic
aneurysm repair. Hemorrhage in this situation is often massive
and fatal unless immediate surgical intervention is undertaken.
Typically, patients with bleeding from an aortoenteric fistula will
present first with a “sentinel bleed.” This is a self-limited episode
that heralds the subsequent massive and often fatal hemorrhage.
This should prompt urgent upper endoscopy because diagnosis at
this stage can be lifesaving. Any evidence of bleeding in the distal
duodenum (third or fourth portion) on EGD should be consid-
ered diagnostic. A computed tomography (CT) scan with intra-
venous administration of contrast material will demonstrate air
around the graft (suggestive of an infection), possible pseudoan-
eurysm, and rarely intravenous contrast material in the duodenal
lumen.
1148 SECTION X Abdomen
FIGURE 46-9 A vascular graft visualized during upper endoscopy for
bleeding. (Courtesy Konrad Rajab, MD, Brigham and Women’s
Hospital.)
Therapy includes ligation of the aorta proximal to the graft,
removal of the infected prosthesis, and extra-anatomic bypass. The
defect in the duodenum is often small and can be repaired primar-
ily. This is a complex and often morbid procedure.
Hemobilia. Hemobilia is often a difficult diagnosis to make. It
is typically associated with trauma, recent instrumentation of the
biliary tree, or hepatic neoplasms. This unusual cause of GI bleed-
ing should be suspected in anyone who presents with hemorrhage,
right upper quadrant pain, and jaundice. Unfortunately, this triad
is seen in less than half of patients, and a high index of suspicion
is required. Endoscopy can be helpful by demonstrating blood at
the ampulla. Angiography is the diagnostic procedure of choice.
If diagnosis is confirmed, angiographic embolization is the pre-
ferred treatment.
Hemosuccus pancreaticus. Another rare cause of upper GI
bleeding is bleeding from the pancreatic duct. This is often caused
by erosion of a pancreatic pseudocyst into the splenic artery. It is
manifested with abdominal pain and hematochezia. As with
hemobilia, it is a difficult diagnosis to make and requires a high
index of suspicion in patients with abdominal pain, blood loss,
and a past history of pancreatitis. Angiography is diagnostic and
permits embolization, which is often therapeutic. In cases that are
amenable to a distal pancreatectomy, the procedure often results
in cure.
Iatrogenic bleeding. Upper GI bleeding may follow therapeu-
tic or diagnostic procedures. As noted, hemobilia may be iatro-
genic in nature, particularly after percutaneous transhepatic
procedures. Endoscopic sphincterotomy represents another
common cause for iatrogenic bleeding, which can occur in up to
2% of cases. It is often mild and self-limited. Late hemorrhage
usually occurs within the first 48 hours and may require injection
of the area with epinephrine. This is usually successful. Surgical
intervention is rarely required.
Percutaneous endoscopic gastrostomy placement is an increas-
ingly common procedure. Bleeding rates of up to 3% have been
reported. Although the majority of these cases reflect bleeding from
FIGURE 46-10 Bleeding from a percutaneous endoscopic gastros-
tomy site. (Courtesy David L. Carr-Locke, MD, Brigham and Women’s
Hospital.)
the incision site, some are due to bleeding from the gastric mucosa
(Fig. 46-10). This can often be controlled endoscopically.
Upper GI bleeding can also be seen in patients who have
recently undergone upper GI surgery. Any of the lesions previ-
ously mentioned could be responsible for postoperative hemor-
rhage, and these possibilities should be considered. In patients in
whom a resection and anastomosis have been performed, the
source of the bleeding may be the suture line or staple line. In
patients in whom this is persistent and an intervention is needed,
endoscopists are often concerned for the potential of suture or
staple line disruption. However, it is safe to do this diagnostic or
even therapeutic endoscopy, provided minimal insufflation is used
and the procedure is done with care.26
Bleeding Related to Portal Hypertension
Upper GI bleeding is a serious complication of portal hyperten-
sion, most often in the setting of cirrhosis. Cirrhosis and portal
hypertension are covered in more detail in Chapter 53; only
bleeding related to portal hypertension is discussed here.
Hemorrhage related to portal hypertension is most commonly
the result of bleeding from varices. These dilated submucosal veins
develop in response to the portal hypertension, providing a col-
lateral pathway for decompression of the portal system into the
systemic venous circulation. They are most common in the distal
esophagus and can reach sizes of 1 to 2 cm. As they enlarge, the
overlying mucosa becomes increasingly tenuous, excoriating with
minimal trauma (Fig. 46-11).
Although these varices are most commonly seen in the esopha-
gus, they may also develop in the stomach and the hemorrhoidal
plexus of the rectum. Portal hypertensive gastropathy, diffuse dila-
tion of the mucosal and submucosal venous plexus of the stomach
associated with overlying gastritis, is an incompletely understood
entity in which the stomach acquires a snakeskin-like appearance
with cherry-red spots. Unlike esophageal varices, it rarely causes
major hemorrhage.
Gastroesophageal varices develop in approximately 30% of
patients with cirrhosis and portal hypertension, and 30% in this
group develop variceal bleeding. Compared with nonvariceal
bleeding, variceal hemorrhage is associated with an increased risk
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1149

of rebleeding, increased need for transfusions, longer hospital
stays, and increased mortality. Hemorrhage is frequently massive,
accompanied by hematemesis and hemodynamic instability. The
hepatic functional reserve, estimated by Child criteria (see Chapter
53), correlates closely with outcomes in these patients. Recent
advances in the field have resulted in a decrease in hospitalization
rates for variceal bleeding.27 Mortality rates have also improved
but still remain high; the 6-week mortality rate after the first
bleeding episode is almost 20%.28 Treatment of variceal bleeding
focuses on two aspects of care: control the acute hemorrhage and
reduce the risk of rebleeding.
Management. Figure 46-12 provides an algorithm for man-
agement. As with other causes of GI bleeding, adequate resuscita-
tion is imperative. Fluid resuscitation in patients with cirrhosis is
FIGURE 46-11 Nonbleeding esophageal varices secondary to cirrho-
sis. (Courtesy David L. Carr-Locke, MD, Brigham and Women’s
Hospital.)
a delicate balance. These patients frequently have hyperaldoste-
ronism associated with fluid retention and ascites. For most of
these patients, early admission to an ICU setting should be con-
sidered. A low threshold for intubation is appropriate. Defects in
coagulation are common and should be aggressively corrected. A
significant percentage of patients with variceal bleeding have
underlying sepsis that may be associated with an aggravation in
portal hypertension and lead to variceal bleeding. Studies have
demonstrated that a 7-day empirical course of a broad-spectrum
antibiotic (e.g., ceftriaxone) will lower the risk of rebleeding.28
Medical management. In patients with cirrhosis, pharmaco-
logic therapy to reduce portal hypertension should be considered
even while preparing for emergent upper endoscopy. Vasopressin
produces splanchnic vasoconstriction and has been shown to sig-
nificantly reduce bleeding compared with placebo. Unfortunately,
this agent results in significant cardiac vasoconstriction, with
resulting myocardial ischemia. Although vasopressin has been
combined with nitroglycerin in clinical practice, somatostatin or
its synthetic analogue, octreotide, is now the vasoactive agent of
choice in the United States. Terlipressin is a newer vasopressin
analogue with reduced side effects that does not need to be used
as a continuous infusion. Terlipressin provides a 3% to 4% relative
risk reduction in mortality in patients with acute variceal hemor-
rhage but is not currently available in the United States.28
Administration of these pharmacologic agents results in tem-
porary control of bleeding and allows time for resuscitation and
performance of the appropriate diagnostic and therapeutic
maneuvers.
Endoscopic management. Early EGD is critical to evaluate
the source of bleeding because more than half of bleeding is
caused by nonvariceal sources, including peptic ulcer, gastritis,
and Mallory-Weiss tears. In fact, studies have suggested that
unlike in peptic ulcer bleeding, early endoscopy (within 15 hours
of presentation) can affect survival in cases of variceal
bleeding.29
Subsequent management is based on the endoscopic findings.
If bleeding esophageal varices are identified, sclerotherapy and

Variceal Bleeding Suspected Based on History

ABC’s and Resuscitation

Start Octreotide or Vasopressin infusion

Variceal bleeding confirmed on EGD

Endoscopic Band Ligation (or Sclerotherapy)

Bleeding Stopped?
Yes No

Octreotide/Vasopressin for 3–5 days Balloon tamponade

Complete 7 days of antibiotics Consider TIPS or surgical shunt
Repeat endoscopic banding every if TPS fails or not available
10–14 days until eliminated

FIGURE 46-12 Algorithm for diagnosis and management of GI hemorrhage related to portal hypertension.
1150 SECTION X Abdomen
variceal banding have been shown to control hemorrhage effec-
tively. Although sclerotherapy, which may use a variety of agents,
is an easier procedure to perform, it is also associated with perfora-
tion, mediastinitis, and stricture. Banding seems to have a lower
complication rate and, when expertise is available, should be the
therapy of choice (Fig. 46-13). These endoscopic approaches,
sometimes with up to three treatments during 24 hours, control
the hemorrhage in up to 90% of patients with esophageal varices.
A have shown that TIPS can control bleeding in 95% of cases.
B controlled, prevention of recurrent hemorrhage should be a prior-
FIGURE 46-13 A, Actively bleeding varices. B, Effective control after
variceal banding. (Courtesy David L. Carr-Locke, MD, Brigham and
Women’s Hospital.)
Unfortunately, gastric varices are not effectively managed by endo-
scopic techniques.
Other management. In cases in which pharmacologic or
endoscopic therapies fail to control the hemorrhage, balloon tam-
ponade can be successful in temporizing the hemorrhage. The
Sengstaken-Blakemore tube consists of a gastric tube with esopha-
geal and gastric balloons. The gastric balloon is inflated and
tension is applied on the gastroesophageal junction. If this does
not control the hemorrhage, the esophageal balloon is inflated as
well, compressing the venous plexus between them. The Minne-
sota tube includes a proximal esophageal lumen for aspirating
swallowed secretions. These tubes are associated with a high rate
of complications related to both aspiration and inappropriate
placement with esophageal perforation. Hemorrhage recurs on
deflation in up to 50% of patients, and the balloon therapy itself
has a 20% to 30% complication rate including aspiration pneu-
monia and esophageal tears. Currently, balloon tamponade is
reserved for patients with massive hemorrhage to permit more
definitive therapies. Recent trials using self-expanding esophageal
stents to control massive variceal hemorrhage have also been
encouraging, but their use remains experimental.30
In cases of refractory variceal bleeding that cannot be con-
trolled endoscopically, emergent portal decompression is indi-
cated. This is required in approximately 10% of patients with
variceal bleeding.31 Although randomized studies have shown
equivalence between a transjugular intrahepatic portosystemic
shunt (TIPS) and surgical shunting in these refractory cases,32 this
is most commonly achieved by means of a percutaneous TIPS,
especially in an unstable patient. The TIPS procedure can be
lifesaving in patients who are hemodynamically unstable from
refractory variceal bleeding and is associated with significantly less
morbidity and mortality than surgical decompression. Studies
Rebleeding occurs in up to 20% within the first month, usually
related to occlusion. Long-term patency rates are even lower,
although many can be salvaged with careful surveillance and per-
cutaneous techniques. In patients for whom TIPS is not available
or fails, emergent surgical intervention is indicated, although this
is seldom necessary today. Emergent surgical options are discussed
in Chapter 53.
Unlike variceal hemorrhage, bleeding from portal hypertensive
gastropathy is not amenable to endoscopic treatment because of
the diffuse nature of the mucosal abnormalities. The underlying
pathologic process involves elevated portal venous pressures, so
pharmacologic therapies aimed at reducing portal venous pressure
are indicated. If pharmacologic therapy fails to control acute
bleeding, TIPS should be considered.33
Rarely, isolated gastric varices occur after splenic vein throm-
bosis. This is most commonly seen in the setting of pancreatitis.
In these patients, central portal pressures are normal, but left-
sided hypertension, decompressed from the spleen to the short
gastric vessels, produces the varices. This is best treated by per-
forming a splenectomy. Although the risk of variceal bleeding was
thought to be high in this group and splenectomy was routinely
recommended, recent data suggest that the incidence of variceal
bleeding is in fact low (4% with a mean follow-up of 34 months),
and splenectomy should not be routinely undertaken.34
Prevention of rebleeding. Once the initial bleeding has been
ity. If no further therapy is undertaken, approximately 70% of
patients will have another bleed within 2 months. The risk of
rebleeding is highest in the initial few hours to days after a first
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1151

episode. Medical therapy to prevent recurrence includes a nonse- TABLE 46-3 Differential Diagnosis of
lective beta blocker, such as nadolol, and an antiulcer agent, such
Lower Gastrointestinal Hemorrhage
as a PPI or sucralfate. These are combined with endoscopic band
ligation repeated every 10 to 14 days until all varices have been SMALL BOWEL
eradicated. COLONIC BLEEDING 95% BLEEDING 5%
Although this aggressive approach results in a significant lower- Diverticular disease 30%-40% Angiodysplasias
ing of the rebleeding rate to less than 20%, it requires intensive Anorectal disease 5%-15% Erosions or ulcers
medical follow-up and supervision.35 In patients who are medi- (potassium, NSAIDs)
cally noncompliant or unable to tolerate such therapy, elective Ischemia 5%-10% Crohn’s disease
portal decompression should be considered if it has not already Neoplasia 5%-10% Radiation
been performed. The choice between TIPS and operative decom- Infectious colitis 3%-8% Meckel’s diverticulum
pression in the stable patient depends on the residual liver func- Post-polypectomy 3%-7% Neoplasia
tion. In general, patients with poor liver reserve who are on the Inflammatory bowel disease 3%-4% Aortoenteric fistula
liver transplant list should be considered for TIPS. This procedure Angiodysplasia 3%
provides a temporizing measure and avoids postoperative scarring Radiation colitis or proctitis 1%-3%
of the porta hepatis, which could complicate the transplant pro- Other 1%-5%
cedure. Unfortunately, TIPS is associated with hepatic encepha- Unknown 10%-25%
lopathy in up to 50% of patients within 1 year of the procedure.36
Other shunt complications, such as thrombosis, can also occur in
up to 30% of patients at 1 year. In those with good liver function sensitive or specific in making an accurate diagnosis in lower GI
who do not qualify for a transplant, surgical decompression is bleeding. Diagnostic evaluation is further complicated by the
therefore preferred. This provides a more endurable long-term observation that in up to 40% of patients with lower GI bleeding,
decompression, with a lower rate of hepatic encephalopathy. In more than one potential source for bleeding is identified. If more
those with good hepatic reserve, these advantages are thought to than one source is identified, it is critical to confirm the respon-
counterbalance the increased operative morbidity and mortality. sible lesion before initiating aggressive therapy. This approach may
The preferred elective shunt is a selective distal splenorenal shunt. occasionally require a period of observation with several episodes
of bleeding before a definitive diagnosis can be made. In fact, in
up to 25% of patients with lower GI hemorrhage, the bleeding
source is never accurately identified.
ACUTE LOWER GASTROINTESTINAL HEMORRHAGE An algorithm for the evaluation of lower GI hemorrhage is
Compared with upper GI hemorrhage, lower GI bleeding is a less shown in Figure 46-14. Once resuscitation has been initiated, the
frequent reason for hospitalization; in fact, in looking at hospital first step in the workup is to rule out anorectal bleeding with a
discharge data in the United States, it is about half as common as digital rectal examination and anoscopy or sigmoidoscopy. With
bleeding from a location proximal to the ligament of Treitz.1 The significant bleeding, it is also important to eliminate an upper GI
number of hospitalizations for this diagnosis, however, is slowly source. An NG aspirate that contains bile and no blood effectively
rising, increasing by 2% between 1998 and 2006. The mortality rules out upper tract bleeding in most patients. However, when
rate of lower GI bleeding is similar to that of upper GI bleeding emergent surgery for life-threatening hemorrhage is being con-
at around 3%, but this rate increases with age to more than 5% templated, preoperative or intraoperative EGD is usually
in those 85 years or older. In more than 95% of patients with appropriate.
lower GI bleeding, the source of hemorrhage is the colon. The Subsequent evaluation depends on the magnitude of the hem-
small intestine is only occasionally responsible, and because these orrhage. With major or persistent bleeding, the workup should
lesions are not typically diagnosed with the combination of upper progress according to the patient’s hemodynamic stability. The
and lower endoscopy, they are considered in the section on obscure truly unstable patient who continues to bleed and requires ongoing
causes of GI bleeding. In general, the incidence of lower GI bleed- aggressive resuscitation belongs in the operating room for expedi-
ing increases with age, and the cause is often age related (Table tious diagnosis and surgical intervention. When hemorrhage is
46-3). Specifically, vascular lesions and diverticular disease affect intermediate, resuscitation and hemodynamic stability permit a
all age groups but have an increasing incidence in middle-aged more directed evaluation and therapeutic intervention. Colonos-
and elderly adults. In the pediatric population, intussusception is copy is the mainstay here because it allows both visualization of
most commonly responsible, whereas Meckel’s diverticulum must the pathologic process and therapeutic intervention in colonic,
be considered in the differential in the young adult. The clinical rectal, and distal ileal sources of bleeding. The usual adjuncts to
presentation of lower GI bleeding ranges from severe hemorrhage colonoscopy include tagged RBC scan and angiography. If these
with diverticular disease or vascular lesions to a minor inconve- modalities are not diagnostic, the source of the hemorrhage is
nience secondary to anal fissure or hemorrhoids.37 considered obscure; such lesions and their evaluation are consid-
ered in the last section of this chapter.
Diagnosis
Lower GI bleeding typically is manifested with hematochezia that Colonoscopy
can range from bright red blood to old clots. If the bleeding is Colonoscopy is most appropriate in the setting of minimal to
slower or from a more proximal source, lower GI bleeding often moderate bleeding; major hemorrhage interferes significantly with
is manifested as melena. Hemorrhage from the lower GI tract visualization, and the diagnostic yield is low. In addition, in the
tends to be less severe and more intermittent and more commonly unstable patient, sedation and manipulation may be associated
ceases spontaneously than upper GI bleeding. Compared with with additional complications and can interfere with resuscita-
endoscopy in upper GI bleeding, no diagnostic modality is as tion. Although the blood is cathartic, gentle preparation with
1152 SECTION X Abdomen

Acute lower gastrointestinal bleeding

Yes Assess for anorectal outlet bleeding

Initiate appropriate therapy Digital rectal exam and anoscopy

No

Rule out upper GI bleeding Yes

Upper GI bleeding algorithm
NGT aspirate or EGD positive

No
Minor bleeding (intermittent) Major bleeding (persistent)

Colonoscopy Stable Unstable

No lesion visualized
Lesion visualized Operating room
and/or continued bleeding

Source Colon or small bowel

uncertain identified as source
Initiate appropriate therapy Small bowel series
Enteroclysis
Positive Enteroscopy
Capsule endoscopy
Subtotal colectomy with
Negative
ileorectal anastomosis or
Repeat colonoscopy small bowel resection
Negative
if rebleeds
Tagged RBC scan

Positive

Segmental resection Angiography and treatment

Localize bleeding:
Serial clamping or intraoperative
enteroscopy followed by resection

FIGURE 46-14 Algorithm for diagnosis and management of lower GI hemorrhage.

polyethylene glycol, either orally or through an NG tube, can
improve visualization. Findings may include an actively bleeding
site, clot adherent to a focus of mucosa or a diverticular orifice,
or blood localized to a specific colonic segment, although this can
be misleading because of retrograde peristalsis in the colon.
Polyps, cancers, and inflammatory causes can frequently be seen.
Unfortunately, angiodysplasias are often difficult to visualize, par-
ticularly in the unstable patient with mesenteric vascular constric-
tion. Diverticula are identified in most patients, whether or not
they are the source of the hemorrhage. Despite these limitations,
the diagnostic yield of colonoscopy in experienced hands is rea-
sonable. Because the majority of lower GI bleeds are self-limited,
the timing of colonoscopy (within 24 hours) and experience of
the colonoscopist are important in identifying the site of hemor-
rhage or stigmata of recent hemorrhage.38
Radionuclide Scanning
Radionuclide scanning with technetium Tc 99m (99mTc-labeled
RBC) is the most sensitive but least accurate method for localiza-
tion of GI bleeding. With this technique, the patient’s own RBCs
are labeled and reinjected. The labeled blood is extravasated into
the GI tract lumen, creating a focus that can be detected scinti-
graphically. Initially, images are collected frequently and then at
4-hour intervals, for up to 24 hours. The RBC scan can detect
bleeding as slow as 0.1 mL/min and is reported to be more than
90% sensitive (Fig. 46-15).39 Unfortunately, the spatial resolution
is low, and blood may move retrograde in the colon or distally in
the small bowel. Reported accuracy of localization is in the range
of only 40% to 60%, and it is particularly inaccurate in distin-
guishing right-sided from left-sided colonic bleeding. The RBC
scan is not usually employed as a definitive study before surgery
but instead as a guide to the utility of angiography; if the RBC
scan is negative or only positive after several hours, angiography
is unlikely to be revealing. Such an approach avoids the significant
morbidity of angiography.
Computed Tomography Angiography
A study has shown that CT angiography may be better than
scintigraphy at localizing the site of GI bleeding. Although sensi-
tivity and specificity of the tests were similar, CT was better at
localizing the site of bleeding, and the findings were more consis-
tent to those at the time of subsequent therapeutic angiography.
 CHAPTER 46 Acute Gastrointestinal Hemorrhage
FIGURE 46-15 A positive RBC scan localizing the bleeding to the left
lower quadrant. (Courtesy Richard A. Baum, MD, Brigham and Women’s
Hospital.)
Although patients in this group received a greater amount of
contrast dye, there was no adverse outcome on renal function.40
Mesenteric Angiography
Selective angiography, using either the superior or inferior mes-
enteric arteries, can detect hemorrhage in the range of 0.5 to
1.0 mL/min and is generally employed only in the diagnosis of
ongoing hemorrhage. It can be particularly useful in identifying
the vascular patterns of angiodysplasias. It may also be used for
localizing actively bleeding diverticula. In addition, it has thera-
peutic capabilities. Catheter-directed vasopressin infusion can
provide temporary control of bleeding, permitting hemodynamic
stabilization, although as many as 50% of patients will rebleed
when the medication is discontinued. It can also be used for
embolization. Although the more limited collateral circulation of
the colon has made this less appealing than in the upper GI tract,
it has been suggested that such techniques can be applied safely
in most patients. Typically, such therapy is reserved for patients
whose underlying condition precludes surgical therapy. Unfortu-
nately, angiography is associated with significant risk of complica-
tions, including hematomas, arterial thrombosis, contrast dye
reactions, and acute renal failure.
Treatment
Therapeutic approaches with lower GI bleeding are clearly depen-
dent on the lesion identified. The criteria for operation, shown in
Box 46-2, are similar to those with upper GI hemorrhage,
although there is a stronger tendency to delay until the site is
clearly localized.
Specific Causes of Lower Gastrointestinal
Tract Bleeding
Colonic Bleeding
Diverticular disease. In the United States, diverticula are the
most common cause of significant lower GI bleeding. In the past,
1153
diverticula were thought to be rare in patients younger than 40
years, but it is now an increasingly common diagnosis in this age
group. Only 3% to 15% of individuals with diverticulosis experi-
ence any bleeding.41 Bleeding generally occurs at the neck of the
diverticulum and is believed to be secondary to bleeding from the
vasa recti as they penetrate through the submucosa. Of those that
bleed, more than 75% stop spontaneously, although approxi-
mately 10% will rebleed within a year and almost 50% within 10
years.39 Although diverticular disease is much more common on
the left side, right-sided disease is responsible for more than half
the bleeding.
The best method of diagnosis and treatment is colonoscopy,
although success is sometimes limited by the large amount of
bleeding. If the bleeding diverticulum can be identified, epineph-
rine injection may control the bleeding. Electrocautery can also
be used, and most recently, endoscopic clips have been success-
fully applied to control the hemorrhage. If bleeding ceases with
these maneuvers or spontaneously, expectant management may be
appropriate; however, this requires clinical judgment based on the
magnitude of the hemorrhage and the patient’s comorbidities,
particularly cardiac disease.
If none of these maneuvers is successful or if hemorrhage
recurs, angiography with embolization can be considered. Super-
selective embolization of the bleeding colonic vessel has gained
popularity with high success rates (>90%), although the risk of
ischemic complications continues to be of concern.42 Under these
circumstances, colonic resection is indicated. Certainty of the site
of bleeding is critical. Blind hemicolectomy is associated with
rebleeding in more than 50% of patients, and operation based on
RBC scan localization alone can result in recurrent hemorrhage
in up to one third of patients.43 Subtotal colectomy does not
eliminate the risk of recurrent hemorrhage and, compared with
segmental resection, is accompanied by a significant increase in
morbidity, particularly diarrhea in older patients, in whom the
remaining rectum may never adapt.
Angiodysplasia. Angiodysplasias of the intestine, also referred
to as arteriovenous malformations, are distinct from hemangio-
mas and true congenital arteriovenous malformations. They are
thought to be acquired degenerative lesions secondary to progres-
sive dilation of normal blood vessels within the submucosa of the
intestine. Angiodysplasias have an equal gender distribution and
are almost uniformly found in patients older than 50 years. These
lesions are notably associated with aortic stenosis and renal failure,
especially in the elderly. The hemorrhage tends to arise from the
right side of the colon, with the cecum being the most common
location, although they can occur in the rest of the colon and
small bowel. Most patients present with chronic bleeding, but in
up to 15%, hemorrhage may be massive. Bleeding stops spontane-
ously in most cases, but approximately 50% will rebleed within
5 years.
These lesions can be diagnosed by either colonoscopy or angi-
ography. During colonoscopy, they appear as red stellate lesions
with a surrounding rim of pale mucosa and can be treated with
sclerotherapy or electrocautery. Angiography demonstrates dilated,
slowly emptying veins and sometimes early venous filling. If these
lesions are discovered incidentally, no further therapy is indicated.
In acutely bleeding patients, they have been successfully treated
with intra-arterial vasopressin, selective gel foam embolization,
endoscopic electrocoagulation, or injection with sclerosing agents.
If these measures fail or bleeding recurs and the lesion has been
localized, segmental resection, most commonly right colectomy,
is effective.
1154 SECTION X Abdomen
Neoplasia. Colorectal carcinoma is an uncommon cause of
significant lower GI hemorrhage but is probably the most impor-
tant one to rule out as more than 150,000 Americans are diag-
nosed each year with this cancer. The bleeding is usually painless,
intermittent, and slow in nature. Frequently, it is associated with
iron deficiency anemia. Polyps can also bleed, but more com-
monly the bleeding occurs after a polypectomy. Although bleed-
ing in the pediatric population is discussed in Chapter 66, juvenile
polyps are the second most common cause of bleeding in patients
younger than 20 years. On occasion, other colonic neoplasms,
most notably GISTs, can be associated with massive hemorrhage.
The best diagnostic tool is colonoscopy. If the bleeding is attribut-
able to a polyp, it can be treated with endoscopic therapy.
Anorectal disease. The major causes of anorectal outlet bleed-
ing are internal hemorrhoids, anal fissures, and colorectal neopla-
sia. Although hemorrhoids are by far the most common of these
entities, they account for only 5% to 10% of all acute lower GI
bleeding. In general, anorectal hemorrhage is low-volume bleed-
ing that is bright red blood per rectum seen in the toilet bowl and
on the toilet paper. Most hemorrhoidal bleeding arises from inter-
nal hemorrhoids; these are painless and often accompanied by
prolapsing tissue that reduces spontaneously or has to be manually
reduced by the patient (Fig. 46-16). Anal fissure, on the other
hand, produces painful bleeding after a bowel movement; bleed-
ing is only occasionally the main symptom in these patients
(Fig. 46-17).
Because anorectal disease is common, a careful investigation to
rule out all other sources of bleeding, especially malignant neo-
plasia, is imperative before lower GI bleeding is attributed to such
disease. Anal fissure can be treated medically with stool bulking
agents (e.g., psyllium [Metamucil]), increased water intake, stool
softeners, and topical nitroglycerin ointment or diltiazem to
relieve sphincter spasm and to promote healing. Internal hemor-
rhoids should be treated with bulking agents, increased dietary
fiber, and adequate hydration. A variety of office-based interven-
tions, including rubber band ligation, injectable sclerosing agents,
and infrared coagulation, have also been used. If these measures
FIGURE 46-16 Bleeding and prolapsed hemorrhoids.
fail, surgical hemorrhoidectomy may be needed. Most anorectal
bleeding is self-limited and responds to dietary and local
measures.
Colitis. Inflammation of the colon is caused by a multitude of
disease processes including inflammatory bowel disease (Crohn’s
disease, ulcerative colitis, and indeterminate colitis), infectious
colitis (O157:H7 Escherichia coli, cytomegalovirus, Salmonella,
Shigella, Campylobacter spp., and Clostridium difficile), radiation
proctitis after treatment for pelvic malignant neoplasms, and
ischemia.
Ulcerative colitis is much more likely than Crohn’s disease to
be manifested with GI bleeding. Ulcerative colitis is a mucosal
disease that starts distally in the rectum and progresses proximally
to occasionally involve the entire colon. Patients can present with
up to 20 bloody bowel movements per day. These are usually
accompanied by crampy abdominal pain and tenesmus. The diag-
nosis is secured by a careful history and flexible endoscopy with
biopsy. Medical therapy with steroids, 5-aminosalicylic acid com-
pounds, and immunomodulatory agents and supportive care are
the mainstays of treatment. Surgical therapy is rarely indicated in
the acute setting unless the patient develops a toxic megacolon or
hemorrhage that is refractory to medical management.
In contrast, Crohn’s disease typically is associated with guaiac-
positive diarrhea and mucus-filled bowel movements but not with
bright red blood. Crohn’s disease can affect the entire GI tract. It
is characterized by skip lesions, transmural thickening of the
bowel wall, and granuloma formation. The diagnosis is made with
endoscopy and contrast studies. Medical management consists of
steroids, antibiotics, immunomodulators, and 5-aminosalicylic
acid compounds. Because Crohn’s disease is a relapsing and remit-
ting disease, surgical therapy is used as a last resort. Massive
colonic hemorrhage complicates ulcerative colitis in up to 15%
of affected patients, whereas it occurs in only 1% of those with
Crohn’s colitis.44
Infectious colitis can cause bloody diarrhea. The diagnosis is
usually established from the history and stool culture. C. difficile
and cytomegalovirus colitis deserve special attention. C. difficile
colitis usually is manifested with explosive, foul-smelling diarrhea
in a patient with prior antibiotic use or hospitalization. Bloody
bowel movements are not common but can be present, especially
in severe cases in which there is associated mucosal sloughing. In
FIGURE 46-17 Anal fissures can be a source of lower GI bleeding.
 CHAPTER 46 Acute Gastrointestinal Hemorrhage
North America, there has been an upsurge in the frequency and
severity of C. difficile–associated colitis. Treatment consists of
stopping antibiotics, supportive care, and oral or intravenous met-
ronidazole or oral vancomycin. Cytomegalovirus colitis should be
suspected in any immunocompromised patient who presents with
bloody diarrhea. Endoscopy with biopsy confirms the diagnosis;
treatment is intravenous ganciclovir.
Radiation proctitis has become much more common in the
last several decades as the use of radiation to treat rectal cancer,
prostate cancer, and gynecologic malignant neoplasms has
increased. Patients present with bright red blood per rectum, diar-
rhea, tenesmus, and crampy pelvic pain. Flexible endoscopy
reveals the characteristic bleeding telangiectasias (Fig. 46-18).
Treatment consists of antidiarrheals, hydrocortisone enemas, and
endoscopic APC. In cases of persistent bleeding, ablation with 4%
formalin solution usually works well.
Mesenteric ischemia. Mesenteric ischemia can be secondary
to either acute or chronic arterial or venous insufficiency. Predis-
posing factors include preexisting cardiovascular disease (atrial
fibrillation, congestive heart failure, and acute myocardial
A sures. Despite improved imaging technology including video
B Repeated Endoscopy
FIGURE 46-18 A, Rectal bleeding secondary to radiation damage.
B, Effective control after application of APC treatment. (Courtesy David
L. Carr-Locke, MD, Brigham and Women’s Hospital.)
1155
infarction), recent abdominal vascular surgery, hypercoagulable
states, medications (e.g., vasopressors and digoxin), and vasculitis.
Acute colonic ischemia is the most common form of mesenteric
ischemia. It tends to occur in the watershed areas of the splenic
flexure and the rectosigmoid colon but can be right sided in up
to 40% of patients. Patients present with abdominal pain and
bloody diarrhea. CT will often show a thickened bowel wall. The
diagnosis is generally confirmed with flexible endoscopy, which
reveals edema, hemorrhage, and a demarcation between the
normal and abnormal mucosa. Treatment focuses on supportive
care consisting of bowel rest, intravenous antibiotics, cardiovascu-
lar support, and correction of the low-flow state. In 85% of cases,
the ischemia is self-limited and resolves without incident, although
some patients develop a colonic stricture. In the other 15% of
cases, surgery is indicated because of progressive ischemia and
gangrene. Marked leukocytosis, fever, a fluid requirement, tachy-
cardia, acidosis, and peritonitis indicate a failure of the ischemia
to resolve and the need for surgical intervention. During the
surgery, resection of the ischemic intestine and creation of an end
ostomy are indicated.45
ACUTE GASTROINTESTINAL HEMORRHAGE
FROM AN OBSCURE SOURCE
Obscure GI hemorrhage is defined as bleeding that persists or
recurs after an initial negative evaluation with EGD and colonos-
copy. Obscure bleeding can be further subdivided into obscure-
occult or obscure-overt bleeding. Obscure-occult bleeding is
characterized by iron deficiency anemia or guaiac-positive stools
without visible bleeding. If initial upper and lower endoscopy fails
to identify a source for obscure-occult bleeding and the patient
has no systemic signs of disease, these patients are often treated
with iron therapy, and more than 80% resolve their symptoms in
less than 2 years. Obscure-overt bleeding is characterized by recur-
rent or persistent visible bleeding.46
Obscure bleeding can be frustrating for both the patient and
the clinician, particularly for obscure-overt bleeding, which
cannot be localized despite obvious signs of bleeding that can be
concerning to patients and necessitate aggressive diagnostic mea-
capsule endoscopy, a source of bleeding may never be found in
some patients. Those patients in whom a diagnosis is reached
often have had multiple tests and several hospitalizations and have
received blood transfusions. Further complicating the manage-
ment of these patients is that obscure GI bleeds have a high rate
of rebleeding; in one study evaluating patients with a negative
capsule endoscopy, the rebleeding rates were 12.9%, 25.6%, and
31.5% at 1, 3, and 5 years, respectively.47 Fortunately, obscure-
overt bleeding is responsible for only about 1% of all GI bleeding.
The differential diagnosis of obscure-overt bleeding is long and
varied (Box 46-3) and includes a variety of small bowel lesions
not previously described. In a series of 200 patients with obscure
bleeding, the small bowel was identified as the source of bleeding
in more than 60% of cases. In these patients, the most common
cause was small bowel ulcers and erosions secondary to Crohn’s
disease, Meckel’s diverticulum, or NSAIDs.48
Diagnosis
The cause of obscure-overt bleeding is often a common lesion that
is missed on initial evaluation. Repeated upper endoscopy and
lower endoscopy are valuable tools in identifying missed lesions
1156 SECTION X Abdomen

BOX 46-3 Differential Diagnosis of performed by administration of 99mTc-pertechnetate that is taken

up by the ectopic gastric mucosa in the diverticulum and localized
Obscure Gastrointestinal Bleeding
with scintigraphy.
Upper Gastrointestinal Colon
Tract Colitis Small Bowel Endoscopy
Angiodysplasia Ulcerative colitis The hemodynamically stable patient should undergo small bowel
Peptic ulcer disease Crohn’s colitis enteroscopy. Usually performed with a pediatric colonoscope, this
Aortoenteric fistula Ischemic colitis is referred to as push endoscopy. It can reach about 50 to 70 cm
Neoplasia Radiation colitis past the ligament of Treitz in most cases and permits endoscopic
HIV-related causes Infective colitis management of some lesions. Overall, push enteroscopy is suc-
Dieulafoy lesion Solitary rectal ulcer cessful in 40% of patients. Sonde pull endoscopy uses an entero-
Lymphoma Amyloidosis scope that passes passively into the very distal small bowel. A
Sarcoidosis Lymphoma balloon on the end of the scope permits normal small bowel
Hemobilia Endometriosis peristalsis to carry the scope into the ileum; the mucosa is visual-
Hemosuccus pancreaticus Angiodysplasia ized as the scope is removed. This technique is cumbersome, does
GAVE Neoplasia not permit intervention, and has largely been abandoned with the
Metastatic cancer HIV-related causes advent of capsule endoscopy.
Hemorrhoids Double-balloon endoscopy is another technique gaining in
Small Bowel popularity. Although technically difficult, this approach is capable
Crohn’s disease of providing a complete examination of the small bowel. In
Meckel’s diverticulum expert hands, double-balloon enteroscopy can identify a bleeding
Lymphoma source in 77% of cases with occult bleeding, with the yield
Radiation enteritis increasing to more than 85% if the endoscopy is performed
Ischemia within 1 month of an overt bleeding episode.48 In cases of acute
HIV-related causes obscure-overt GI bleed, a study found that more bleeding lesions
Bacterial infection were identified by double-balloon endoscopy performed within
Metastatic disease 72 hours of admission than by video capsule endoscopy.49 The
Angiodysplasia advantage of double-balloon endoscopy is that as well as visual-
NSAID-induced erosions ization, biopsies can be performed and therapeutic interventions
undertaken.

as up to 35% of patients will have the bleeding source identified
on second-look endoscopy. Most obscure GI hemorrhage is from
a source distal to the ligament of Treitz. When repeated endoscopy
fails to identify an obscure-overt bleeding source, investigation of
the small bowel is warranted. This should proceed in an orderly
fashion, depending on the degree of bleeding and the patient’s
hemodynamic status.
Conventional Imaging
The next step is probably a tagged RBC scan, although its utility
in this setting has not been established, and as discussed previ-
ously, it may be misleading. Angiography may be more useful but
usually requires significant ongoing hemorrhage. Provocative
testing, which involves administration of anticoagulants, fibrino-
lytics, or vasodilators to increase hemorrhage during angiography,
has been employed in small series with favorable results, but
reluctance to induce uncontrolled hemorrhage has limited its use.
Small bowel enteroclysis, which uses a tube to infuse barium,
methylcellulose, and air directly into the small bowel, provides
better imaging than simple small bowel follow-through. Because
the yield has been reported to be very low and the test is poorly
tolerated, it is now rarely used. An alternative to small bowel
enteroclysis is CT enterography, which can identify gross lesions
such as small bowel tumors and inflammatory conditions such as
Crohn’s disease. The limitation of small bowel radiography is that
it cannot visualize angiodysplasias, the main cause of obscure
small bowel hemorrhage.
In younger patients, usually younger than 30 years, part of
the initial evaluation should be a Meckel’s diverticulum scan. A
Meckel’s diverticulum with ectopic acid-secreting mucosa can
ulcerate the small bowel and produce bleeding. This scan is
Video Capsule Endoscopy
Capsule endoscopy uses a small capsule with a video camera,
which is swallowed and acquires video images as it passes through
the GI tract. This modality permits visualization of the entire GI
tract but offers no interventional capability and is also time-
consuming because someone has to watch the video to identify
the bleeding source. This procedure is usually well tolerated,
although it is contraindicated in patients with obstruction or a
motility disorder. Capsule endoscopy is frequently used in the
patient who is hemodynamically stable but continues to bleed.
This technique has reported success rates as high as 90% in iden-
tifying small bowel disease. However, in a large national review of
capsule endoscopy in obscure GI bleeding, the test failed to iden-
tify a source of bleeding in 30% to 40% of both obscure-occult
and obscure-overt cases.50
Intraoperative Endoscopy
Intraoperative enteroscopy should be reserved for patients who
have transfusion-dependent obscure-overt bleeding in whom an
exhaustive search has failed to identify a bleeding source. This
typically uses a pediatric colonoscope introduced through the
mouth or through an enterotomy in the small bowel made by
the surgeon. In the latter case, a sterile colonoscope is passed onto
the field, introduced into the small bowel, and passed bidirection-
ally with the surgeon assisting to pass the bowel over the endo-
scope. Any suspicious areas are marked for possible resection or
are dealt with endoscopically if feasible.
Treatment
Obscure GI hemorrhage requires a careful approach to diagnosis
and management. Specific causes and their management are listed
 CHAPTER 46 Acute Gastrointestinal Hemorrhage 1157

in the following section. Up to 25% of cases of obscure lower GI the diagnosis of diverticula, and in the absence of other sources
hemorrhage remain without a diagnosis, and 33% to 50% of of bleeding, it may be assumed that the diverticula are the source
patients will rebleed within 3 to 5 years.46 Management strategies of bleeding. In cases of profuse bleeding, angiography or intraop-
generally depend on the identification of a lesion. Iron replace- erative endoscopy may be used to identify the bleeding source.
ment combined with intermittent transfusion is occasionally nec-
essary, although this approach is not appealing. If possible, patients
who are taking anticoagulants (e.g., warfarin, NSAIDs, aspirin, SELECTED REFERENCES
or clopidogrel) should be encouraged to stop these medications
Barkun AN, Bardou M, Kuipers EJ, et al: International consensus
to lower rebleeding risks.50
recommendations on the management of patients with nonvari-
Specific Causes of Small Bowel Bleeding ceal upper gastrointestinal bleeding. Ann Intern Med 152:101–
113, 2010.
Angiodysplasias
Angiodysplasias are a common cause of small intestinal bleeding,
An update on international consensus on management of
accounting for 10% to 20%.50 Most small intestinal vascular
upper GI bleeds.
ectasias appear to occur in the jejunum, followed by the ileum
and then the duodenum. The usual diagnostic tools are generally
Gralnek IM: Obscure-overt gastrointestinal bleeding. Gastroenter-
unsuccessful in identifying these lesions. Angiography is rarely
ology 128:1424–1430, 2005.
positive. Instead, most small bowel vascular lesions require enter-
oscopy or capsule endoscopy for identification. In cases of severe
A concise discussion of the diagnostic approach to obscure
hemorrhage requiring emergent operative intervention, intraop-
bleeding, including the roles of small bowel fiberoptic and
erative endoscopy may be helpful. These lesions have a high
capsule endoscopy.
rebleeding rate, and segmental small bowel resection may be
required. On occasion, these lesions may be diffuse; this may
Herrera JL: Management of acute variceal bleeding. Clin Liver Dis
occur in heredity hemorrhagic telangiectasia (Osler-Weber-Rendu
18:347–357, 2014.
syndrome), acute renal failure, or von Willebrand disease. In this
situation, there has been limited experience with estrogen and
A review on current management of variceal bleeding.
progesterone treatment, but it has been suggested that these agents
may be of benefit.
Rockey DC: Gastrointestinal bleeding. Gastroenterol Clin North
Neoplasia Am 34:581–588, 2005.
Small bowel tumors are not common but can be sources of occult
A monograph covering all aspects of gastrointestinal
or frank GI bleeding. Bleeding typically results from erosion of
hemorrhage.
the mucosa overlying the tumor. GISTs have the greatest propen-
sity for bleeding. Small bowel tumors are typically diagnosed by
Sung JJ: Marshall and Warren Lecture 2009: Peptic ulcer bleed-
small bowel contrast series or spiral CT scan. Treatment involves
ing: An expedition of 20 years from 1989–2009. J Gastroenterol
surgical resection.
Hepatol 25:229–233, 2010.
Crohn’s Disease
A review archiving the evolution of current endoscopic, phar-
Patients with Crohn’s disease may also present with small bowel
macologic, and surgical management of upper GI bleeding.
bleeding in association with terminal ileitis. Bleeding is not gener-
There is also a discussion of some of the current
ally significant, nor is it usually the only presenting symptom. It
controversies.
is diagnosed by small bowel contrast series, and initial treatment
is medical.

Meckel’s Diverticulum
REFERENCES
Meckel’s diverticulum is a true diverticulum in that it contains all
layers of the small bowel wall. It is a congenital remnant of the
omphalomesenteric duct, occurring in approximately 2% of the
general population. Often, heterotopic tissue is present at the base
of the diverticulum. Bleeding from a Meckel’s diverticulum is
usually from an ulcerative lesion on the ileal wall opposite the diver-
ticulum, resulting from acid production by ectopic gastric mucosa.
If nuclear medicine imaging is negative and bleeding is relatively
brisk, angiography may be helpful in the diagnosis. Surgical man-
agement usually requires a segmental resection to incorporate the
opposing ileal mucosa, which is typically the site of bleeding.
Diverticula
Unlike a Meckel’s diverticulum, small intestinal diverticula are
false diverticula that do not involve all layers of the bowel. Bleed-
ing from small bowel diverticula can present a diagnostic challenge.
Capsule endoscopy or small intestinal contrast studies can confirm
1. Zhao Y, Encinosa W: Hospitalizations for gastrointestinal
bleeding in 1998 and 2006: Statistical brief #65 , Rockville,
Md, 2006, Healthcare Cost and Utilization Project (HCUP)
Statistical Briefs.
2. Abougergi MS, Travis AC, Saltzman JR: The in-hospital mor-
tality rate for upper GI hemorrhage has decreased over 2
decades in the United States: A nationwide analysis. Gastro-
intest Endosc 81:882–888, e1, 2015.
3. Cryer BL, Wilcox CM, Henk HJ, et al: The economics of
upper gastrointestinal bleeding in a US managed-care setting:
A retrospective, claims-based analysis. J Med Econ 13:70–77,
2010.
4. Quan S, Frolkis A, Milne K, et al: Upper-gastrointestinal
bleeding secondary to peptic ulcer disease: Incidence
and outcomes. World J Gastroenterol 20:17568–17577,
2014.
1158 SECTION X Abdomen
5. Meltzer AC, Klein JC: Upper gastrointestinal bleeding:
Patient presentation, risk stratification, and early manage-
ment. Gastroenterol Clin North Am 43:665–675, 2014.
6. Tata LJ, Fortun PJ, Hubbard RB, et al: Does concurrent
prescription of selective serotonin reuptake inhibitors and
non-steroidal anti-inflammatory drugs substantially increase
the risk of upper gastrointestinal bleeding? Aliment Pharmacol
Ther 22:175–181, 2005.
7. Rubin TA, Murdoch M, Nelson DB: Acute GI bleeding in
the setting of supratherapeutic international normalized ratio
in patients taking warfarin: Endoscopic diagnosis, clinical
management, and outcomes. Gastrointest Endosc 58:369–373,
2003.
8. Tsoi KK, Ma TK, Sung JJ: Endoscopy for upper gastrointes-
tinal bleeding: How urgent is it? Nat Rev Gastroenterol Hepatol
6:463–469, 2009.
9. Sarin N, Monga N, Adams PC: Time to endoscopy and
outcomes in upper gastrointestinal bleeding. Can J Gastroen-
terol 23:489–493, 2009.
10. Enestvedt BK, Gralnek IM, Mattek N, et al: An evaluation
of endoscopic indications and findings related to nonvariceal
upper-GI hemorrhage in a large multicenter consortium.
Gastrointest Endosc 67:422–429, 2008.
11. Cheng CL, Lee CS, Liu NJ, et al: Overlooked lesions at
emergency endoscopy for acute nonvariceal upper gastroin-
testinal bleeding. Endoscopy 34:527–530, 2002.
12. Barkun AN, Bardou M, Kuipers EJ, et al: International con-
sensus recommendations on the management of patients
with nonvariceal upper gastrointestinal bleeding. Ann Intern
Med 152:101–113, 2010.
13. Rockey DC: Gastrointestinal bleeding. Gastroenterol Clin
North Am 34:581–588, 2005.
14. Wang YR, Richter JE, Dempsey DT: Trends and outcomes
of hospitalizations for peptic ulcer disease in the United
States, 1993 to 2006. Ann Surg 251:51–58, 2010.
15. Sung JJ: Marshall and Warren Lecture 2009: Peptic ulcer
bleeding: An expedition of 20 years from 1989-2009. J Gas-
troenterol Hepatol 25:229–233, 2010.
16. Schilling D, Demel A, Nusse T, et al: Helicobacter pylori
infection does not affect the early rebleeding rate in patients
with peptic ulcer bleeding after successful endoscopic hemo-
stasis: A prospective single-center trial. Endoscopy 35:393–
396, 2003.
17. Gisbert JP, Khorrami S, Carballo F, et al: H. pylori eradication
therapy vs. antisecretory non-eradication therapy (with or
without long-term maintenance antisecretory therapy) for
the prevention of recurrent bleeding from peptic ulcer.
Cochrane Database Syst Rev (4):CD004062, 2003.
18. Liu CC, Lee CL, Chan CC, et al: Maintenance treatment
is not necessary after Helicobacter pylori eradication and
healing of bleeding peptic ulcer: A 5-year prospective, ran-
domized, controlled study. Arch Intern Med 163:2020–2024,
2003.
19. Hippisley-Cox J, Coupland C, Logan R: Risk of adverse
gastrointestinal outcomes in patients taking cyclo-oxygenase-2
inhibitors or conventional non-steroidal anti-inflammatory
drugs: Population based nested case-control analysis. BMJ
331:1310–1316, 2005.
20. Chan FK, To KF, Wu JC, et al: Eradication of Helicobacter
pylori and risk of peptic ulcers in patients starting long-term
treatment with non-steroidal anti-inflammatory drugs: A
randomised trial. Lancet 359:9–13, 2002.
21. Malfertheiner P, Megraud F, O’Morain C, et al: Current
concepts in the management of Helicobacter pylori infection:
The Maastricht III Consensus Report. Gut 56:772–781,
2007.
22. Lau JY, Sung JJ, Lam YH, et al: Endoscopic retreatment
compared with surgery in patients with recurrent bleeding
after initial endoscopic control of bleeding ulcers. N Engl J
Med 340:751–756, 1999.
23. Guglielmi A, Ruzzenente A, Sandri M, et al: Risk assessment
and prediction of rebleeding in bleeding gastroduodenal
ulcer. Endoscopy 34:778–786, 2002.
24. Chung IK, Kim EJ, Lee MS, et al: Endoscopic factors pre-
disposing to rebleeding following endoscopic hemostasis in
bleeding peptic ulcers. Endoscopy 33:969–975, 2001.
25. Nguyen DC, Jackson CS: The Dieulafoy’s lesion: An update
on evaluation, diagnosis, and management. J Clin Gastroen-
terol 49:541–549, 2015.
26. Stiegmann GV: Endoscopic approaches to upper gastrointes-
tinal bleeding. Am Surg 72:111–115, 2006.
27. Jamal MM, Samarasena JB, Hashemzadeh M, et al: Declin-
ing hospitalization rate of esophageal variceal bleeding in the
United States. Clin Gastroenterol Hepatol 6:689–695, quiz
605, 2008.
28. Herrera JL: Management of acute variceal bleeding. Clin
Liver Dis 18:347–357, 2014.
29. Hsu YC, Chung CS, Tseng CH, et al: Delayed endoscopy as
a risk factor for in-hospital mortality in cirrhotic patients
with acute variceal hemorrhage. J Gastroenterol Hepatol
24:1294–1299, 2009.
30. Dechene A, El Fouly AH, Bechmann LP, et al: Acute man-
agement of refractory variceal bleeding in liver cirrhosis by
self-expanding metal stents. Digestion 85:185–191, 2012.
31. Chalasani N, Kahi C, Francois F, et al: Improved patient
survival after acute variceal bleeding: A multicenter, cohort
study. Am J Gastroenterol 98:653–659, 2003.
32. Henderson JM, Boyer TD, Kutner MH, et al: Distal spleno-
renal shunt versus transjugular intrahepatic portal systematic
shunt for variceal bleeding: A randomized trial. Gastroenterol-
ogy 130:1643–1651, 2006.
33. Lo GH, Liang HL, Chen WC, et al: A prospective, random-
ized controlled trial of transjugular intrahepatic portosys-
temic shunt versus cyanoacrylate injection in the prevention
of gastric variceal rebleeding. Endoscopy 39:679–685, 2007.
34. Heider TR, Azeem S, Galanko JA, et al: The natural history
of pancreatitis-induced splenic vein thrombosis. Ann Surg
239:876–880, discussion 880–882, 2004.
35. de la Pena J, Brullet E, Sanchez-Hernandez E, et al: Variceal
ligation plus nadolol compared with ligation for prophylaxis
of variceal rebleeding: A multicenter trial. Hepatology 41:572–
578, 2005.
36. Riggio O, Angeloni S, Salvatori FM, et al: Incidence, natural
history, and risk factors of hepatic encephalopathy after
transjugular intrahepatic portosystemic shunt with
polytetrafluoroethylene-covered stent grafts. Am J Gastroen-
terol 103:2738–2746, 2008.
37. Ghassemi KA, Jensen DM: Lower GI bleeding: Epide-
miology and management. Curr Gastroenterol Rep 15:333,
2013.
38. Niikura R, Nagata N, Aoki T, et al: Predictors for identifica-
tion of stigmata of recent hemorrhage on colonic diverticula
in lower gastrointestinal bleeding. J Clin Gastroenterol
49:e24–e30, 2015.
 CHAPTER 46 Acute Gastrointestinal Hemorrhage
39. Strate LL: Lower GI bleeding: Epidemiology and diagnosis.
Gastroenterol Clin North Am 34:643–664, 2005.
40. Jacovides CL, Nadolski G, Allen SR, et al: Arteriography for
lower gastrointestinal hemorrhage: Role of preceding abdom-
inal computed tomographic angiogram in diagnosis and
localization. JAMA Surg 150:650–656, 2015.
41. Niikura R, Nagata N, Shimbo T, et al: Natural history of
bleeding risk in colonic diverticulosis patients: A long-term
colonoscopy-based cohort study. Aliment Pharmacol Ther
41:888–894, 2015.
42. Lipof T, Sardella WV, Bartus CM, et al: The efficacy and
durability of super-selective embolization in the treatment of
lower gastrointestinal bleeding. Dis Colon Rectum 51:301–
305, 2008.
43. Bender JS, Wiencek RG, Bouwman DL: Morbidity and mor-
tality following total abdominal colectomy for massive lower
gastrointestinal bleeding. Am Surg 57:536–540, discussion
540–541, 1991.
44. Pardi DS, Loftus EV, Jr, Tremaine WJ, et al: Acute major
gastrointestinal hemorrhage in inflammatory bowel disease.
Gastrointest Endosc 49:153–157, 1999.
1159
45. Walker AM, Bohn RL, Cali C, et al: Risk factors for colon
ischemia. Am J Gastroenterol 99:1333–1337, 2004.
46. Gralnek IM: Obscure-overt gastrointestinal bleeding. Gastro-
enterology 128:1424–1430, 2005.
47. Magalhaes-Costa P, Bispo M, Santos S, et al: Re-bleeding
events in patients with obscure gastrointestinal bleeding after
negative capsule endoscopy. World J Gastrointest Endosc
7:403–410, 2015.
48. Shinozaki S, Yamamoto H, Yano T, et al: Long-term outcome
of patients with obscure gastrointestinal bleeding investigated
by double-balloon endoscopy. Clin Gastroenterol Hepatol
8:151–158, 2010.
49. Aniwan S, Rerknimitr R, Kongkam P, et al: A combination
of clinical risk stratification and fecal immunochemical test
results to prioritize colonoscopy screening in asymptomatic
participants. Gastrointest Endosc 81:719–727, 2015.
50. Min YW, Kim JS, Jeon SW, et al: Long-term outcome of
capsule endoscopy in obscure gastrointestinal bleeding: A
nationwide analysis. Endoscopy 46:59–65, 2014.